Revenue
No reported data
BriaCell Therapeutics Corp. (BCTX)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2024
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Research & development | $21.3M | $27.2M | $15.3M | $8.0M | $2.0M | $2.4M | — |
| Operating expenses | $27.2M | $33.3M | $23.3M | — | $7.0M | $3.9M | — |
| Operating income | −$27.2M | −$33.3M | −$23.3M | −$15.3M | −$7.0M | −$3.9M | — |
| EBITDAderived | −$27.1M | −$33.2M | — | −$15.3M | −$7.0M | −$3.9M | — |
| Net income | −$26.3M | −$4.8M | −$20.3M | −$26.8M | −$13.8M | −$4.0M | −$4.7M |
| Basic EPSper diluted share | -$62.19 | -$43.68 | -$1.30 | -$1.73 | -$3.06 | — | — |
| Diluted EPSper diluted share | -$62.19 | -$43.68 | -$1.30 | -$1.73 | — | — | — |